Experimental drug aims to tame severe asthma and COPD attacks

NCT ID NCT07705737

Not yet recruiting Disease control Sponsor: Connect Biopharm LLC Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This trial tests a single dose of rademikibart, given intravenously, as an add-on treatment for people hospitalized with an acute asthma or COPD flare-up who also have type 2 inflammation. The study includes 40 adults and measures how well the drug improves lung function and controls symptoms. The goal is to see if this approach can speed recovery and reduce the need for standard steroid treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rademikibart (also called CBP-201), given as a single 300 mg IV push
What this could lead to: If successful, this could provide a new option to quickly control severe asthma or COPD flare-ups and reduce the need for oral steroids.
What could go wrong: This is a small, early-phase trial with no placebo group, so results may not prove effectiveness. The drug may also cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute asthma asthma chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA ACUTE COPD EXACERBATION ACUTE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Columbus Clinical Services, LLC

Miami, Florida, 33135, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.